Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Elanco Drug Lands FDA Approval

Monday, January 22, 2018 11:49 AM EDT Updated: Monday, January 22, 2018 12:03 PM EDT
By Alex Brown
Elanco Drug Lands FDA Approval Elanco is headquartered in Greenfield.

Greenfield-based Elanco Animal Health has received U.S. Food and Drug Administration approval for its new monthly flea and tick treatment for dogs. The company says the approval of Credelio rounds out its portfolio of companion animal parasiticides.

Credelio is an oral treatment that targets the nervous system receptors of ticks and fleas. In a news release Monday, Elanco Animal Health Director of Regional Consulting Tony Rumschlag said, "When choosing pet medications, veterinarians and pet owners are most concerned with safety for the pet as well as efficacy of the product. Lotilaner, the active ingredient in Credelio, was selected from hundreds of candidate molecules with this in mind. (Credelio) is fast-acting and effective against ticks and fleas, while being easy on dogs and puppies."

Elanco Animal Health did not provide a timeline for availability of Credelio. The announcement of the drug’s FDA approval comes more than a week after the company received European approval for its drug Galliprant, which is designed to treat pain associated with mild-to-moderate osteoarthritis in dogs. 

Story Continues Below

Most Popular Stories

Perspectives

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

In the hustle and bustle of our professional lives, we often find ourselves engrossed in the intricacies of our trades. However, amidst our daily routines, there exists a unique opportunity to broaden our horizons and delve into the critical issues facing the state of Indiana. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service